Advantages of Technological Platforms
Youngen has developed a Fast Integrated Screening Technology called FlSTsiran that is uniquely positioned to rapidly identify RNA molecules with potent activity, long durability and superior safety.
As a center for drug evaluation, Youngen has developed a Multi-targeted Single-entity Technology called MSTsiran that is capable of incorporating two or more different siRNAs. This technology could be applied to treat many complex diseases that are caused by the dysregulation of more than one gene or multiple diseases.
As a biopharmaceutical research company, Youngen has developed a siRNA Transport Technology called STTsiran that can significantly enhance the activity of siRNA drugs in extra-hepatic tissues. This technology enables tissue specific targeting including the brain, muscle, and adipose.
If you want to know more about technology achievements, please visit our website.
Breakthrough drug designation is a special review channel by FDA for new drugs treating serious/life-threatening diseases with unmet clinical needs, providing policy supports including faster review, R&D communication guidance and priority review eligibility to accelerate innovative drugs' access to patients.
You must be logged in to post a comment.